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Abstract
Background: Transcatheter aortic valve implantation (TAVI) has proven to be a valid option for patients with severe
aortic stenosis who are at high perioperative risk, particularly in patients with previous cardiac surgery. Several
patients with previous mitral valve surgery were reported to have been successfully treated with TAVI.
Case presentation: Two patients, one with mechanical and one with biological mitral valve prosthesis, presented with
symptomatic severe aortic stenosis. After discussion among our multidisciplinary heart team transapical approach and a
JenaValve™ prosthesis was used for TAVI. Main reasons were to decrease the perioperative risk, avoid a re-opening of the
chest via median sternotomy, and discuss the possible superiority of the JenaValve™ device due to its design. The
patients were successfully treated and discharged on the 11th and 14th post-operative day, respectively.
Echocardiographic follow up before discharge and up to 2.8 years post-operatively showed excellent results.
Conclusions: In conclusion, TAVI in patients with preexisting mitral prostheses-mechanical or biological-is feasible, safe,
and effective and offers a valid alternative to conventional aortic valve replacement in this particular re-operation scenario.
The JenaValve™ device does not interact with the mitral prosthesis and offers therefore due to its unique design a
potential advantage.
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Background
Considerable proportion of patients who require mitral
valve replacement (MVR) presents with a coexisting path-
ology of the aortic valve [1, 2] with a possible necessity of
surgery of the aortic valve in the following years. On the
other hand, the perioperative risk of morbidity and mortal-
ity is elevated in patients undergoing conventional aortic
valve replacement with previous median sternotomy [3].
Transcatheter aortic valve implantation (TAVI) is now-
adays an approved treatment for aortic stenosis (AS) in
patients who are at high surgical risk [4] and it can fur-
ther reduce perioperative risk especially in patients who
had undergone previous cardiac surgery as there is po-
tentially less surgical trauma [5]. Nevertheless, previous
coronary artery bypass grafting (CABG), aortic valve
replacement (AVR) or mitral valve replacement pose
unknown risks when TAVI is performed.
We report two cases of severe AS treated by transapi-
cal TAVI in patients who underwent previously MVR
with a mechanical and biological valve, respectively.
Case presentation
The first case is a 76 year old patient presented to our
hospital with progressive dyspnea, currently NYHA class
III (New York Heart Association) and recurrent cardiac
decompensation with a right pleural effusion and con-
secutive dystelectasis. Diagnostics, including transthoracic
(TTE) and transesophageal echocardiography (TEE), re-
vealed a severe aortic valve stenosis (Δpmean = 83 mmHg,
effective orifice area (EOA) = 0.4 cm2) [6]. The selective
coronary angiography identified a coronary sclerosis with-
out significant stenosis. In consequence to his severe mi-
tral valve vitium the patient received a 27 mm bileaflet
mechanical mitral valve prosthesis (Carbomedics, Sorin
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Group, Milano, Italy) 17 years prior to the current symp-
tomatic episode. Echocardiographic survey showed no
signs of malfunction of the mitral valve prosthesis. Due to
the medical history including chronic atrial fibrillation and
mechanical mitral valve prosthesis the patient received
anticoagulant therapy (vitamin K antagonists). Additional
comorbidities are listed in Table 1. The patient was suffer-
ing from pre-renal, recently compensated chronic kidney
insufficiency and had a history of duodenal ulcers,
ischemic colitis, and bladder carcinoma.
The second case is a 74 year old patient complaining
about progressive dyspnea (NYHA III) and episodes of
stable load-dependent angina pectoris. Diagnostics also
identified a severe aortic valve stenosis (TTE: Δpmean =
41 mmHg; cardiac catheter: Δpmean = 35 mmHg, EOA =
0.7 cm2 (according to Gorlin formula)) and coronary
angiography showed still open bypasses after coronary
artery bypass grafting in 2011. Due to chronic atrial
fibrillation the patient received therapy with vitamin K
antagonists as well. In addition to the preoperative demo-
graphics (Table 1), the patient received a pacemaker 4
years ago, because of bradyarrhythmia and was suffering
from chronic lymphatic leukemia, recently in remission.
In contrast to the first case, this patient received a 27 mm
biological mitral valve prosthesis (Perimount Plus,
Carpentier-Edwards, Irvine, USA) in 2011 with still excel-
lent function.
Preoperative risk evaluation of perioperative mortality
using the EuroSCORE (European System for Cardiac
Operative Risk Evaluation) and the STS-Score (Society
of Thoracic Surgeons) showed a high perioperative risk
for both patients (Table 1). Furthermore, the patients
strictly denied surgical aortic valve replacement via
median sternotomy.
The cases were discussed by our multidisciplinary team
of interventional cardiologists and cardiac surgeons as rec-
ommended [7] and after considering preoperative diag-
nostics and all available treatment options, a transapical
approach for transcatheter aortic valve implantation was
favored. The annulus size of the aortic valve as well as the
optimal angulation was determined preoperatively with
gated CTA (Computed Tomography Angiography). The
procedure was performed in general anesthesia in a fully
equipped hybrid operating room as described previously
[8]. An anterolateral approach via the 5th intercostal space
was used for exposure of the apex. Rapid pacing was
applied for balloon aortic valvuloplasty with a 22 mm bal-
loon (NuCLEUS™, pfm medical AG, Cologne, Germany).
A self-expandable prosthesis (27 mm JenaValve™,
JenaValve Technology GmbH, Munich, Germany) was im-
planted in typical manner after positioning with optimal
angulation without rapid pacing or hemodynamic instabil-
ity. Neither transesophageal echocardiography nor aortog-
raphy identified a para- or transvalvular regurgitation in
both cases (Fig. 1a, b). The patients were either extubated
in the operating room or shortly after being transferred to
the intensive care unit for further monitoring. Patient one
was discharged on the 11th postoperative day (POD), pa-
tient two on POD 14. Follow up examinations (before dis-
charge, in the rehabilitation facility and 2.8 or 1.3 years
postoperatively, respectively) were performed and both
patients presented with dyspnea according to NYHA II
without echocardiographic evidence of paravalvular leak-
age at each point in time (Table 2). In the last examin-
ation, mean transaortic pressure gradient was 17 and
18 mmHg, respectively.
Conclusions
After a few reports about implanting JenaValve™ in pa-
tients with mechanical mitral valve prosthesis [9, 10], we
report here a case of transcatheter aortic valve implant-
ation using the self-expandable JenaValve™ in a patient
with history of biological mitral valve prosthesis.
Patients with symptomatic aortic valve stenosis that
qualify for transcatheter implantation with pre-existing
Table 1 Preoperative demographics
Patient 1 Patient 2
Age [y] 76 74
Sex Male Male
EOA [cm2] 0.4 0.7




LVEF [%] 61 65
NYHA-class III III










COPD [GOLD] IV III
PHT Moderate Severe
PAD [Fontaine] II II
EuroSCORE I [%] 32.83 55.56
EuroSCORE II [%] 11.61 11.08
STS-score, PROM [%] 5.52 6.72
(CABG coronary artery bypass grafting, CCS Canadian Cardiovascular Society,
COPD chronic obstructive pulmonary disease, EOA effective orifice area, EOAI
effective orifice area index, EuroSCORE European System for Cardiac Operative
Risk Evaluation, LVEF left ventricular ejection fraction, MVR Mitral valve
replacement, NYHA New York Heart Association, PAD peripheral arterial
disease-fontaine classification, PHT pulmonary hypertension, Pre-Op Δpmean
preoperative mean transaortic pressure gradient, STS-score, PROM Society of
Thoracic Surgeons-score, predictive risk of mortality, y years)
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both, biological or mechanical mitral valve prostheses,
are still a rare but increasing entity [1]. On the other
hand, the perioperative risk of morbidity and mortality is
elevated in patients undergoing conventional aortic valve
replacement with previous median sternotomy [3]. Since
TAVI-procedures were performed patients with pre-
existing heart valve prostheses can be offered a new valid
therapy option.
The first case of AS treated by TAVI in a patient with
previous MVR was reported by Rodes-Gabau in 2008 [11].
Since then further publications reported the use of transa-
pical [9–15], transfemoral [15–20] and even direct aortic
[19] approaches to replace a severely stenotic aortic valve
following MVR with different types of mechanical and
biological mitral valve prostheses [9–21] or mitral valve
reconstructions [19]. Possible complications, the risk of
embolization or interference due to the mitral prosthesis’
struts, may complicate those procedures [13, 17]. There-
fore, such patients were excluded from the Partner trial
[22] and Medtronic CoreValve U.S. Pivotal Trial [23].
In contrast to the right ventricle with its dedicated
outflow tract the left ventricle has a common aortic-
mitral orifice with a close anatomical and physiological
relationship between the aortic and mitral valve. The
presence of a prosthetic mitral valve reduces the aortic-
mitral distance and can therefore complicate an aortic
valve implantation [24]. Additionally, the presence of a
rigid mechanical structure instead of fibrotic tissue
contributes to aggravate the situation [12]. These two
mechanisms are the main causes for insufficient opening
of the transcatheter valves, dislocation [13] or
embolization [11]. Thus, despite good positioning of the
CoreValve® prosthesis (Medtronic Inc., Minneapolis,
USA), it can interfere with the opening of the mitral
prosthesis’ leaflets and cause a life-threatening situation
[17]. Yet an excessively high implantation can lead to
aortic regurgitation or even worse occlusion of the cor-
onary arteries [25]. Even dislocating of the Edwards Sa-
pien® (Edwards Lifesciences, Irvine, CA) aortic valve
prosthesis into the left ventricle 2 weeks after implant-
ation has been reported [13].
In pre-existing biological mitral valve prosthesis,
which have a different configuration compared to
mechanical mitral valve prosthesis with more
prominent commissural struts reaching into the left
ventricular outflow tract (LVOT), TAVI procedure is
even more challenging. Balloon displacement toward
the aorta during inflation and valve malposition or
embolization has been reported when implanting
balloon expandable prostheses [12].
A minimum distance between the mitral valve pros-
thesis and the aortic annulus is recommended in both,
self-expanding and balloon expandable TAVI to avoid a
potential mitral valve dysfunction and to allow the cor-
rect expansion of the aortic valve prosthesis [20, 26].
Therefore, preprocedural screening of the patients and
particularly the evaluation of mitro-aortic distance
should be done precisely by multislice computed tomog-
raphy [20]. Preoperative and intraprocedural transesoph-
ageal echocardiography, as well as fluoroscopy is also
essential, to ensure a careful assessment of the patients’
anatomy and to monitor a precise device deployment.
Fig. 1 TAVI in a patient with a mechanical mitral valve prosthesis and b biological mitral valve prosthesis
Table 2 Intra- and postoperative data
Patient 1 Patient 2
Skin-to-skin time [min] 63 52
Ventilation time [h] 10 0
ICU-stay [d] 3 1
Total hospital stay [d] 11 14
Aortic regurgitation discharge None None
Paravalvular leakage discharge None None
ΔPmean [mmHg] discharge 10 14
NYHA-class discharge II II
Paravalvular leakage follow up None None
ΔPmean [mmHg] follow up 17 18
Mitral prosthesis dysfunction follow up None None
d days, h hours, ICU intensive care unit, NYHA New York Heart Association,
ΔPmean mean transaortic pressure gradient
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According to our experience, the JenaValve™ is more
securing in this setting. Because the locators of the Jena-
Valve™ are positioned into the nadir of the aortic valve
sinus the lower margin does not reach more than 2 mm
into the LVOT below the aortic annulus and thus offer-
ing a reasonable safe distance that is needed to prevent
interference with the mitral valve prosthesis during de-
ployment [9]. The possibility of recapturing and reposi-
tioning of the device during deployment is also one
major advantage to ensure optimal positioning of the
prosthesis. Furthermore, a shorter valve length will pre-
vent asymmetrical deployment thus decreasing the risk
of paravalvular leakage [9].
For choosing a transapical versus a transfemoral ap-
proach, recommendations should be followed [27], yet a
transapical approach was suggested to be more advanta-
geous [12] due to more efficient prosthesis maneuvers.
Our report and the previous experience with Jena-
Valve™ [9, 10] suggest that the JenaValve™ prosthesis may
offer a potential advantage over other prostheses, due to
its design, when implanted in patients with previous mi-
tral valve replacement. However, larger series are needed
to proof the anticipated superiority of the JenaValve™ de-
vice over other prosthesis.
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